TR201903066T4 - E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi. - Google Patents
E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi. Download PDFInfo
- Publication number
- TR201903066T4 TR201903066T4 TR2019/03066T TR201903066T TR201903066T4 TR 201903066 T4 TR201903066 T4 TR 201903066T4 TR 2019/03066 T TR2019/03066 T TR 2019/03066T TR 201903066 T TR201903066 T TR 201903066T TR 201903066 T4 TR201903066 T4 TR 201903066T4
- Authority
- TR
- Turkey
- Prior art keywords
- coli
- production
- recombinant vaccine
- enzymatic conjugation
- glycoconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201903066T4 true TR201903066T4 (tr) | 2019-03-21 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/03066T TR201903066T4 (tr) | 2012-11-07 | 2013-11-07 | E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (https=) |
| EP (3) | EP3508579B1 (https=) |
| JP (2) | JP6412875B2 (https=) |
| KR (1) | KR20150079964A (https=) |
| CN (1) | CN105008539B (https=) |
| AU (2) | AU2013343520B2 (https=) |
| BR (1) | BR112015010283A8 (https=) |
| CA (2) | CA2889767C (https=) |
| EA (1) | EA201590705A1 (https=) |
| ES (3) | ES2882282T3 (https=) |
| IL (1) | IL238586A0 (https=) |
| MX (1) | MX366912B (https=) |
| SG (1) | SG11201503308XA (https=) |
| TR (1) | TR201903066T4 (https=) |
| WO (1) | WO2014072405A1 (https=) |
| ZA (1) | ZA201503097B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2501406T3 (https=) * | 2009-11-19 | 2018-05-19 | ||
| MX371513B (es) | 2013-10-11 | 2020-01-31 | Glaxosmithkline Biologicals Sa | Metodos de modificacion de celulas huespedes. |
| WO2015124769A1 (en) | 2014-02-24 | 2015-08-27 | Glycovaxyn Ag | Novel polysaccharide and uses thereof |
| CA2945542C (en) * | 2014-04-17 | 2024-03-05 | Glycovaxyn Ag | Modified host cells and uses thereof |
| WO2016020499A2 (en) | 2014-08-08 | 2016-02-11 | Glycovaxyn Ag | Modified host cells for use in bioconjugate production |
| ES3039659T3 (en) * | 2015-02-26 | 2025-10-23 | Vaxnewmo Llc | Acinetobacter o-oligosaccharyltransferases and uses thereof |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB201712678D0 (en) * | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| US11235046B2 (en) | 2017-11-04 | 2022-02-01 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| JP2021528059A (ja) | 2018-06-16 | 2021-10-21 | ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ | グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用 |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| US12350342B2 (en) | 2018-12-21 | 2025-07-08 | Vaxnewmo Llc | O-linked glycosylation recognition motifs |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| CN112369722B (zh) * | 2020-05-08 | 2023-03-17 | 湖北中烟工业有限责任公司 | 加热不燃烧装置和温度控制方法 |
| WO2021255684A1 (en) * | 2020-06-18 | 2021-12-23 | Glaxosmithkline Biologicals Sa | Shigella-tetravalent (shigella4v) bioconjugate |
| WO2021259743A2 (en) | 2020-06-25 | 2021-12-30 | Glaxosmithkline Biologicals Sa | Vaccine |
| AU2021342797B2 (en) | 2020-09-17 | 2024-02-08 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995031548A1 (en) * | 1994-05-16 | 1995-11-23 | The Uab Research Foundation | Streptococcus pneumoniae capsular polysaccharide genes and flanking regions |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| IL163806A0 (en) | 2002-03-07 | 2005-12-18 | Eidgenoess Tech Hochschule | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| ES2353814T3 (es) | 2005-05-11 | 2011-03-07 | Eth Zuerich | Proteinas n-glicosiladas recombinantes de celulas procariotas. |
| CN101983070B (zh) | 2008-02-20 | 2016-03-30 | 格林考瓦因有限公司 | 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物 |
| JP5841044B2 (ja) * | 2009-03-23 | 2016-01-06 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 複合糖質ワクチン |
| JP2012533285A (ja) | 2009-07-17 | 2012-12-27 | オーシャン ハーベスト テクノロジー （カナダ） インコーポレイテッド | 魚用飼料中の合成添加物を置換する、天然かつ持続可能な海藻配合物 |
| EP3281639B1 (en) | 2010-05-06 | 2020-11-11 | GlaxoSmithKline Biologicals S.A. | Capsular gram-positive bacteria bioconjugate vaccines |
| ES2905107T3 (es) * | 2012-10-12 | 2022-04-07 | Glaxosmithkline Biologicals Sa | Procedimientos de modificación de células hospedadoras |
-
2013
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en not_active Ceased
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja not_active Expired - Fee Related
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en not_active Ceased
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh not_active Expired - Fee Related
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Withdrawn
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en not_active Ceased
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en not_active Expired - Fee Related
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201903066T4 (tr) | E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi. | |
| EA201890389A2 (ru) | Композиции конъюгата xten и способы их получения | |
| ZA201601534B (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| PH12015502493B1 (en) | Compositions and methods for modulating hbv and ttr expression | |
| EA201890942A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
| MX2023010178A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
| PH12014501229A1 (en) | Antibody-drug conjugates and related compounds, compositions, and methods | |
| MX2013010286A (es) | Conjugados de amatoxinas con enlaces mejorados. | |
| SG10201900948PA (en) | Modified nucleotide linkers | |
| EA201200091A1 (ru) | Штаммы talaromyces и ферментные композиции | |
| PH12013500386A1 (en) | Pesticidal compositions | |
| MX2016007063A (es) | Peptidos terapeuticos. | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| EA201290876A1 (ru) | Композиции индуцированных дендритных клеток и их использование | |
| MX2013004353A (es) | Produccion recombinante de n-propanol e isopropanol. | |
| IN2012DN02210A (https=) | ||
| FI20115328A0 (fi) | Uusia kutinaaseja, niiden tuottaminen ja käytöt | |
| GB201017519D0 (en) | Vaccines | |
| GB201110777D0 (en) | Methods and uses | |
| BR112016007671A2 (pt) | adição em estágio tardio de modificador de reologia | |
| MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
| MX2014010958A (es) | Composicion de celulas inmunoestimuladora activada y sus usos. | |
| RU2010119250A (ru) | Штамм bifidobacterium adolescentis рвв-1, используемый для получения продукции | |
| NZ708737A (en) | Thrombin solution and methods of use thereof |